In the study, the scientists screened known drugs and identified small molecules that could replace conventional reprogramming genes, which can have dangerous side effects. This new process offers a new way to generate stem cells from fibroblasts, a general cell type that is abundant and easily accessible from various tissues, including skin.
The study was published in the November 6, 2008 edition (Volume 3, Issue 5) of the journal Cell Stem Cell.
"Our study shows for the first time that somatic or general cell types can be reprogrammed with only two genes and small molecules, and that these small molecules can replace one of the two most essential reprogramming genes," said Sheng Ding, a Scripps Research scientist and Associate Professor in the Department of Chemistry, who led the study with colleagues from Scripps Research and the Max Planck Institute for Molecular Biomedicine in Germany. "In this case, we replaced the Sox2 gene, which had previously always been regarded as absolutely essential for the reprogramming process."
The SOX2 gene encodes a transcription factor that plays a critical role in the regulation of embryonic stem cells.
"This proof-of-principle study leads us one step closer to the ultimate reprogramming of general cells to pluripotent cells in a completely chemically defined manner without genetic manipulation," he said. "In conjunction with our earlier published studies, it offers definitive proof that we can make cell reprogramming technology much more practical than it has been."
Ding went on to suggest that this drug discovery approach could be used to identify additional small molecules, which could not only provide insights into the reprogramming process, but also become useful in in vivo stem cell biology and, ultimately, the development of novel therapeutics.
This kind of chemical approach to the generation of useful stem cells offers more precise control over the proces
'/>"/>
| Contact: Keith McKeown kmckeown@scripps.edu 858-784-8134 Scripps Research Institute Source:Eurekalert |